Selective PPARγ modulators for Type 2 diabetes treatment: how far have we come and what does the future hold?

Future Med Chem. 2018 Apr 1;10(7):703-705. doi: 10.4155/fmc-2018-0021. Epub 2018 Apr 19.

Authors

Antonio Lavecchia¹, Carmen Cerchia¹

Affiliation

¹ Department of Pharmacy, 'Drug Discovery' Laboratory, University of Napoli 'Federico II', Via D. Montesano, 49, 80131, Napoli, Italy.

PMID: 29671628
DOI: 10.4155/fmc-2018-0021

No abstract available

Keywords: PPARγ; Type 2 diabetes; metabolic disorders; nuclear receptors; partial agonists; selective modulators.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Humans
Hydrogen Bonding
Hypoglycemic Agents / chemistry
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use*
Ligands
Models, Molecular
PPAR gamma / agonists*
PPAR gamma / chemistry
PPAR gamma / metabolism
Structure-Activity Relationship

Substances

Hypoglycemic Agents
Ligands
PPAR gamma